Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698132 | Clinical Oncology | 2017 | 11 Pages |
Abstract
Currently there is considerable interest in combining anti-PD-1 or PD-L1 monoclonal antibodies with established standard of care therapies such as radiotherapy. Radiotherapy is known to be immunostimulatory and efforts are underway to combine and augment the efficacy of the immune checkpoint inhibitors further. This review outlines the interaction between lung cancer and the immune system, summarises current evidence supporting the use of monoclonal antibodies targeting the PD-1 axis in lung cancer and explores the potential of combining radiotherapy with immunotherapy to augment anti-tumour immune responses.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
R. Marshall, A. Popple, T. Kordbacheh, J. Honeychurch, C. Faivre-Finn, T. Illidge,